Acumen Pharmaceuticals reported a better-than-expected earnings per share (EPS) of -$0.33 for the first quarter of 2026, surpassing the forecasted -$0.37. This represents a 10.81% positive surprise.
Despite the earnings beat, the company's stock fell 3.11% in pre-market trading to $2.49 and further declined 0.54% to $2.377, reflecting cautious investor sentiment.
The company demonstrated improved financial performance, focusing on disciplined cost management while investing in clinical development, particularly the Enhanced Brain Delivery (EBD) program. Completion of enrollment in the ALTITUDE-ad trial marks a significant milestone.
Executives highlighted their cost management strategy and successful capital raise, extending the cash runway into early 2027. They remain optimistic about the EBD program and the upcoming ALTITUDE-ad trial results.
